Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.